ARALEN, chloroquine phosphate, USP, is a 4-aminoquinoline compound for oral administration. It is a white, odorless, bitter tasting, crystalline substance, freely soluble in water.
ARALEN is indicated for the suppressive treatment and for acute attacks of malaria due to
P. vivax, P. malariae, P. ovale, and susceptible strains of
P. falciparum. The drug is also indicated for the treatment of extraintestinal amebiasis.
ARALEN does not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. It is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. In patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of
Media Articles Related to Aralen (Chloroquine)
Significant Retinopathy Risk With Long-Term Hydroxychloroquine
Source: Medscape Ophthalmology Headlines [2014.10.15]
Long-term use of hydroxychloroquine may carry a significant risk of toxic retinopathy, according to a retrospective case-control study.
Reuters Health Information
Faslodex and tamoxifen combo reverse tamoxifen-resistant breast cancer
Source: Lupus News From Medical News Today [2014.06.17]
The inexpensive anti-malarial drug hydroxychloroquine (HCQ) reverses resistance to tamoxifen, a widely used breast cancer drug, in mice.
Published Studies Related to Aralen (Chloroquine)
Randomized trial of hydroxychloroquine for newly diagnosed chronic
graft-versus-host disease in children: a Children's Oncology Group study. 
The Children's Oncology Group conducted a multicenter Phase III trial for chronic
graft-versus-host disease (cGVHD). The double-blind, placebo-controlled,
randomized study evaluated hydroxychloroquine added to standard therapy for
children with newly diagnosed cGVHD...
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. [2011.11]
BACKGROUND: Chloroquine (CQ) remains the treatment of choice for Plasmodium vivax malaria. Initially confined to parts of Indonesia and Papua, resistance of P. vivax to CQ seems to be spreading, and alternative treatments are required... CONCLUSIONS: The efficacy of CQ in the treatment of P. vivax infections is declining on the Thai-Myanmar border. DP is an effective alternative treatment.
Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. [2011.09]
BACKGROUND: Chloroquine has in-vitro activity against influenza and could be an ideal candidate for worldwide prevention of influenza in the period between onset of a pandemic with a virulent influenza strain and the development and widespread dissemination of an effective vaccine. We aimed to assess the efficacy of such an intervention... INTERPRETATION: Although generally well tolerated by a healthy community population, chloroquine does not prevent infection with influenza. Alternative drugs are needed for large-scale prevention of influenza. FUNDING: National Medical Research Council, Singapore. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Clinical trial of extended-dose chloroquine for treatment of resistant falciparum malaria among Afghan refugees in Pakistan. [2011.06.23]
BACKGROUND: Falciparum malaria is a significant problem for Afghan refugees in Pakistan. Refugee treatment guidelines recommended standard three-day chloroquine treatment (25 mg/kg) for first episodes and extended five-day treatment (40 mg/kg) for recrudescent infections, based on the assumption that a five-day course would more likely achieve a cure. An in-vivo randomized controlled trial was conducted among refugees with uncomplicated falciparum malaria to determine whether five-day treatment (CQ40) was more effective than standard treatment (CQ25)... CONCLUSIONS: CQ is not suitable for first-line falciparum treatment in Afghan refugee communities. The extended-dose CQ regimen can overcome 39% of resistant infections that would recrudesce under the standard regimen, but the high failure rate after directly observed treatment demonstrates its use is inappropriate.
Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. [2011.01.18]
CONCLUSION: Pyronaridine-artesunate efficacy in acute uncomplicated P. vivax malaria was at least that of chloroquine. As pyronaridine-artesunate is also efficacious against P. falciparum malaria, this combination has potential utility as a global antimalarial drug. TRIAL REGISTRATION: Clinicaltrials.gov NCT00440999.
Clinical Trials Related to Aralen (Chloroquine)
Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India [Completed]
This primary objective of this study is to assess whether the combination of Azithromycin
with chloroquine is non-inferior to the combination of sulfadoxine-pyrimethamine plus
chloroquine, when used to treat uncomplicated cases of malaria due to Plasmodium falciparum
in adults in India.
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) [Recruiting]
The purpose of this study is to test the hypothesis that chloroquine will reduce the ability
of ductal carcinoma in situ (DCIS) to survive and spread. Participants will receive either
chloroquine standard dose (500mg/week) or chloroquine low dose (250mg/week) for 1 month
prior to surgical removal of the tumor.
Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly [Not yet recruiting]
This randomized clinical trial will address a complication related to recurrent episodes of
malaria in endemic areas - hyper-reactive malarial splenomegaly. We aim to assess the
efficacy of chloroquine after prednisone-induction therapy compared to standard treatment
of chloroquine alone in the treatment of adult patients with newly diagnosed hyper-reactive
Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer [Not yet recruiting]
Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients [Not yet recruiting]
Chloroquine might very well be able to increase overall survival in small cell lung cancer
by sensitizing cells resistant to chemotherapy and radiotherapy.
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Aralen has an overall score of 1. The effectiveness score is 6 and the side effect score is 4. The scores are on ten point scale: 10 - best, 1 - worst.
Aralen review by 20 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Moderately Effective|
|Side effects:|| || Severe Side Effects|
|Condition / reason:|| || malaria|
|Dosage & duration:|| || 2/3 (dosage frequency: everyday) for the period of 2 days|
|Other conditions:|| || fever,stomach upset,nausea|
|Other drugs taken:|| || multivitamins|
|Benefits:|| || my fever was reduced but just for a while, as i threw up almost every 30 minutes after taking the medication and and until i emptied my stomach, the nausea was constant with every intake of the drug .|
|Side effects:|| || compulsive vomiting,nausea,headaches and intense shivering|
|Comments:|| || 2 tabs to be taken 3times daily for the duration of the treatment alongside aspirin.|
Page last updated: 2014-10-15